More than alternative estrogen receptors: the emerging role of GPER-1 and ERα36 in breast cancer

Abstract

Breast cancer classification and therapeutic decision-making have traditionally relied on the evaluation of estrogen receptor alpha (ERα), PR, and HER2, yet this framework does not fully explain tumor heterogeneity, endocrine resistance, or estrogen responsiveness in ERα-negative contexts. Emerging evidence implicates non-genomic estrogen signaling mediated by membrane-associated receptors such as G protein-coupled estrogen receptor 1 (GPER-1) and ERα36. Acting as interconnected signaling nodes, these receptors activate MAPK/ERK and PI3K/AKT pathways and engage in crosstalk with receptors such as EGFR, promoting proliferation, cellular plasticity, and adaptive responses. Here, we propose an integrative framework based on three axes: endocrine resistance in ERα-positive tumors, estrogen responsiveness in ERα-negative subtypes, and environmental modulation of signaling. Within this model, GPER-1 and ERα36 form a coordinated network that extends beyond genomic mechanisms and converges on shared downstream effectors. These pathways also intersect with post-transcriptional regulation, tumor-microenvironment interactions, and extracellular vesicle-mediated communication, contributing to tumor progression and metastasis. Environmental ligands, such as bisphenol A, may further modulate signaling intensity, reinforcing plasticity and resistance phenotypes. Collectively, GPER-1 and ERα36 emerge as candidate biomarkers with diagnostic and therapeutic relevance. Their integration into multi-omics and functional classification strategies may refine breast cancer stratification and support more precise therapeutic approaches.

Keywords

GPER-1 / ERα36 / non-genomic estrogen signaling / endocrine resistance / breast cancer subtypes / breast cancer heterogeneity / biomarkers / BPA

References

[1] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378: 771-84.

[2] Nass N, Kalinski T. Tamoxifen resistance: from cell culture experiments towards novel biomarkers. Pathol Res Pract. 2015; 211: 189-97.

[3] Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025; 10: 49.

[4] Pal M, Das D, Pandey M. Understanding genetic variations associated with familial breast cancer. World J Surg Oncol. 2024; 22: 271.

[5] Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62: 233-47.

[6] Liang F, Peng L, Wu Z, Giamas G, Stebbing J. Design and reporting of phase III oncology trials with prospective biomarker validation. J Natl Cancer Inst. 2023; 115: 174-80.

[7] Liu H, Karsidag I, Golin R, Wu G. Bridging Discovery and Treatment: Cancer Biomarker. Cancers (Basel). 2025; 17: 3720.

[8] Girgert R, Emons G, Gründker C. Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER. Front Endocrinol (Lausanne). 2019; 9: 781.

[9] Wang K, Li ZL, Huang LY, Yao CJ, Crawford DR, Wang CY, et al. Integrin αvβ3 as a Non-Genomic Estrogen Receptor in Breast Cancer for Signaling Pathways and Crosstalk. Cells. 2025; 14: 1832.

[10] Yin L, Wang ZY. Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance. Steroids. 2016; 111: 95-9.

[11] Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004; 6: 240-5.

[12] Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR Jr, Lee DH, et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev. 2012; 33: 378-455.

[13] Louis GW, Hallinger DR, Stoker TE. The effect of triclosan on the uterotrophic response to extended doses of ethinyl estradiol in the weanling rat. Reprod Toxicol. 2013; 36: 71-7.

[14] Jones LP, Sampson A, Kang HJ, Kim HJ, Yi YW, Kwon SY, et al. Loss of BRCA1 leads to an increased sensitivity to Bisphenol A. Toxicol Lett. 2010; 199: 261-8.

[15] Atlas E, Dimitrova V. Bisphenol S and Bisphenol A disrupt morphogenesis of MCF-12A human mammary epithelial cells. Sci Rep. 2019; 9: 16005.

[16] Molina L, Figueroa CD, Ehrenfeld P. Interaction of Bisphenol A with G Protein: Coupled Receptors: New Paradigms in Breast Cancer. In: Bisphenols. IntechOpen; 2021.

[17] Qie Y, Qin W, Zhao K, Liu C, Zhao L, Guo LH. Environmental Estrogens and Their Biological Effects through GPER Mediated Signal Pathways. Environ Pollut. 2021; 278: 116826.

[18] Shen T, Brandwein-Gensler M, Hameed O, Siegal GP, Wei S. Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. Hum Pathol. 2015; 46: 1776-84.

[19] Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020; 6: 54.

[20] Prossnitz ER, Barton M. The G protein-coupled oestrogen receptor GPER in health and disease: an update. Nat Rev Endocrinol. 2023; 19: 407-24.

[21] Pagano MT, Ortona E, Dupuis ML. A Role for Estrogen Receptor alpha36 in Cancer Progression. Front Endocrinol (Lausanne). 2020; 11: 506.

[22] Yu T, He C, Zhang H, Zhu Y, Wang A, Zeng X, et al. Endocrine therapy resistance of breast cancer: Important role of G protein-coupled estrogen receptor (GPER) and new therapeutic strategies. Genes Dis. 2025; 13: 101716.

[23] Molina L, Figueroa CD, Ehrenfeld P. Bisphenols and Their Interaction with GPER-1: The Invisible Enemy Behind Breast Cancer and Its Societal Impact. In: Pharmaceutical Science. IntechOpen; 2024.

[24] Thiebaut C, Konan HP, Guerquin MJ, Chesnel A, Livera G, Le Romancer M, et al. The Role of ERα36 in Development and Tumor Malignancy. Int J Mol Sci. 2020; 21: 4116.

[25] Gu W, Dong N, Wang P, Shi C, Yang J, Wang J. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro. Cell Biol Toxicol. 2017; 33: 183-95.

[26] Molina Calistro L, Arancibia Y, Olivera MA, Domke S, Torres RF. Interaction of GPER-1 with the endocrine signaling axis in breast cancer. Front Endocrinol (Lausanne). 2025; 16: 1494411.

[27] Zhang X, Deng H, Wang ZY. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells. J Steroid Biochem Mol Biol. 2014; 143: 434-43.

[28] Yu T, Liu M, Luo H, Wu C, Tang X, Tang S, et al. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells. J Steroid Biochem Mol Biol. 2014; 143: 392-403.

[29] Fahlén M, Zhang H, Löfgren L, Masironi B, VON Schoultz E, VON Schoultz BO, et al. Expression of Estrogen Receptors in Relation to Hormone Levels and the Nottingham Prognostic Index. Anticancer Res. 2016; 36: 2839-47.

[30] Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer--An overview and update. Mol Cell Endocrinol. 2015; 418 Pt 3: 220-34.

[31] Wang ZY, Yin L. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer. Mol Cell Endocrinol. 2015; 418 Pt 3: 193-206.

[32] Cignarella A, Boscaro C, Albiero M, Bolego C, Barton M. Post-Transcriptional and Epigenetic Regulation of Estrogen Signaling. J Pharmacol Exp Ther. 2023; 386: 288-97.

[33] Liu J, Wang F, Zhang Y, Liu J, Zhao B. ADAR1-Mediated RNA Editing and Its Role in Cancer. Front Cell Dev Biol. 2022; 10: 956649.

[34] Chen SY, Chen SY, Yang S, Li Y, Yang SY. ADAR1-mediated RNA editing in breast cancer: molecular mechanisms and therapeutic implications. Med Oncol. 2025; 42: 421.

[35] Tekin B, Ekizoglu S, Kaya SB, Guven M, Trabulus DC. ADAR1 gene expression and its importance in breast cancer. Cancer Genet. 2025; 296-297: 106-10.

[36] Li X, Huang T. Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer. Breast Cancer. 2025; 32: 1216-43.

[37] Schiffer L, Barnard L, Baranowski ES, Gilligan LC, Taylor AE, Arlt W, et al. Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review. J Steroid Biochem Mol Biol. 2019; 194: 105439.

[38] Coelingh Bennink HJ. Are all estrogens the same? Maturitas. 2004; 47: 269-75.

[39] Zhu J, Zhou Y, Jin B, Shu J. Role of estrogen in the regulation of central and peripheral energy homeostasis: from a menopausal perspective. Ther Adv Endocrinol Metab. 2023; 14: 20420188231199359.

[40] Tal R, Taylor HS. Endocrinology of Pregnancy. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.

[41] O’Malley BW, Khan S. Elwood V. Jensen (1920-2012): father of the nuclear receptors. Proc Natl Acad Sci U S A. 2013; 110: 3707-8.

[42] Božović A, Mandušić V, Todorović L, Krajnović M. Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases. Int J Mol Sci. 2021; 22: 1656.

[43] Song D, He H, Indukuri R, Huang Z, Stepanauskaite L, Sinha I, et al. ERα and ERβ Homodimers in the Same Cellular Context Regulate Distinct Transcriptomes and Functions. Front Endocrinol (Lausanne). 2022; 13: 930227.

[44] Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci. 2023; 24: 6834.

[45] Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential. Steroids. 2014; 90: 13-29.

[46] Belachew EB, Sewasew DT. Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer. Front Endocrinol (Lausanne). 2021; 12: 599586.

[47] Vrtačnik P, Ostanek B, Mencej-Bedrač S, Marc J. The many faces of estrogen signaling. Biochem Med (Zagreb). 2014; 24: 329-42.

[48] Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E. Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. J Breast Health. 2015; 11: 59-66.

[49] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49.

[50] Kashyap A, Rapsomaniki MA, Barros V, Fomitcheva-Khartchenko A, Martinelli AL, Rodriguez AF, et al. Quantification of tumor heterogeneity: from data acquisition to metric generation. Trends Biotechnol. 2022; 40: 647-76.

[51] Lopez-Knowles E, Detre S, Hills M, Schuster EF, Cheang MCU, Tovey H, et al. Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study. Breast Cancer Res. 2022; 24: 61.

[52] Makhlouf S, Quinn C, Toss M, Alsaleem M, Atallah NM, Ibrahim A, et al. Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance. Eur J Cancer. 2024; 197: 113473.

[53] Takano EA, Younes MM, Meehan K, Spalding L, Yan M, Allan P, et al. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival. BMC Cancer. 2023; 23: 459.

[54] Acramel A, Jacquot Y. Deciphering of a Putative GPER Recognition Domain in ERα and ERα36. Front Endocrinol (Lausanne). 2022; 13: 943343.

[55] Ranganathan P, Nadig N, Nambiar S. Non-canonical Estrogen Signaling in Endocrine Resistance. Front Endocrinol (Lausanne). 2019; 10: 708.

[56] Pepermans RA, Sharma G, Prossnitz ER. G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives. Cells. 2021; 10: 672.

[57] Pupo M, Bodmer A, Berto M, Maggiolini M, Dietrich PY, Picard D. A genetic polymorphism repurposes the G-protein coupled and membrane-associated estrogen receptor GPER to a transcription factor-like molecule promoting paracrine signaling between stroma and breast carcinoma cells. Oncotarget. 2017; 8: 46728-44.

[58] Belcher SM. Rapid signaling mechanisms of estrogens in the developing cerebellum. Brain Res Rev. 2008; 57: 481-92.

[59] Filardo EJ, Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab. 2005; 16: 362-7.

[60] Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005; 146: 624-32.

[61] Prossnitz ER, Arterburn JB. International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators. Pharmacol Rev. 2015; 67: 505-40.

[62] Molina L, Figueroa CD, Bhoola KD, Ehrenfeld P. GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: therapeutic coupling to breast cancer. Expert Opin Ther Targets. 2017; 21: 755-66.

[63] Xu S, Yu S, Dong D, Lee LTO. G Protein-Coupled Estrogen Receptor: A Potential Therapeutic Target in Cancer. Front Endocrinol (Lausanne). 2019; 10: 725.

[64] Samartzis EP, Noske A, Meisel A, Varga Z, Fink D, Imesch P. The G protein-coupled estrogen receptor (GPER) is expressed in two different subcellular localizations reflecting distinct tumor properties in breast cancer. PLoS One. 2014; 9: e83296.

[65] Xu F, Ma J, Wang X, Wang X, Fang W, Sun J, et al. The Role of G Protein-Coupled Estrogen Receptor (GPER) in Vascular Pathology and Physiology. Biomolecules. 2023; 13: 1410.

[66] Talia M, Cirillo F, Scordamaglia D, Di Dio M, Zicarelli A, De Rosis S, et al. The G Protein Estrogen Receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer. J Exp Clin Cancer Res. 2024; 43: 171.

[67] Pepermans RA, Prossnitz ER. ERα-targeted endocrine therapy, resistance and the role of GPER. Steroids. 2019; 152: 108493.

[68] Manzoor MF, Tariq T, Fatima B, Sahar A, Tariq F, Munir S, et al. An insight into bisphenol A, food exposure and its adverse effects on health: A review. Front Nutr. 2022; 9: 1047827.

[69] Vandenberg LN, Maffini MV, Schaeberle CM, Ucci AA, Sonnenschein C, Rubin BS, et al. Perinatal exposure to the xenoestrogen bisphenol-A induces mammary intraductal hyperplasias in adult CD-1 mice. Reprod Toxicol. 2008; 26: 210-9.

[70] Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco EM, Abonante S, et al. Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ Health Perspect. 2012; 120: 1177-82.

[71] Yu L, Das P, Vall AJ, Yan Y, Gao X, Sifre MI, et al. Bisphenol A induces human uterine leiomyoma cell proliferation through membrane-associated ERα36 via nongenomic signaling pathways. Mol Cell Endocrinol. 2019; 484: 59-68.

[72] Fitzgerald AC, Peyton C, Dong J, Thomas P. Bisphenol A and Related Alkylphenols Exert Nongenomic Estrogenic Actions Through a G Protein-Coupled Estrogen Receptor 1 (Gper)/Epidermal Growth Factor Receptor (Egfr) Pathway to Inhibit Meiotic Maturation of Zebrafish Oocytes. Biol Reprod. 2015; 93: 135.

[73] Senarath Pathirajage K, Rajapaksa G. Long-term exposure to environmentally relevant Bisphenol-A levels affects growth, swimming, condition factor, sex ratio and histology of juvenile zebrafish. Sci Rep. 2024; 14: 24503.

[74] Weber Lozada K, Keri RA. Bisphenol A increases mammary cancer risk in two distinct mouse models of breast cancer. Biol Reprod. 2011; 85: 490-7.

[75] Feng J, Mazari ME, Yasmin S, Riaz A, Uddin J, Hussain AI, et al. Impact of bisphenol A exposure on fetal brain development and neurological health-a review. Environ Sci: Adv. 2025; 5: 43-58.

[76] Hafezi SA, Abdel-Rahman WM. The Endocrine Disruptor Bisphenol A (BPA) Exerts a Wide Range of Effects in Carcinogenesis and Response to Therapy. Curr Mol Pharmacol. 2019; 12: 230-8.

[77] Roberts-Thomson SJ, Chalmers SB, Monteith GR. The Calcium-Signaling Toolkit in Cancer: Remodeling and Targeting. Cold Spring Harb Perspect Biol. 2019; 11: a035204.

[78] Molina Calistro L, Arancibia Y, Alarcón J, Torres RF. The Ca²⁺ Bridge: From Neurons to Circuits in Rett Syndrome. Int J Mol Sci. 2025; 26: 10490.

[79] Weis WI, Kobilka BK. The Molecular Basis of G Protein-Coupled Receptor Activation. Annu Rev Biochem. 2018; 87: 897-919.

[80] Fei J, Guo Y. MAPK/ERK Signaling in Tumorigenesis: mechanisms of growth, invasion, and angiogenesis. EXCLI J. 2025; 24: 854-79.

[81] Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36: 320-8.

[82] Gagliardi PA, Pertz O. The mitogen-activated protein kinase network, wired to dynamically function at multiple scales. Curr Opin Cell Biol. 2024; 88: 102368.

[83] Hao J, Bao X, Jin B, Wang X, Mao Z, Li X, et al. Ca2+ channel subunit α 1D promotes proliferation and migration of endometrial cancer cells mediated by 17β-estradiol via the G protein-coupled estrogen receptor. FASEB J. 2015; 29: 2883-93.

[84] Filardo EJ, Thomas P. Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology. 2012; 153: 2953-62.

[85] Scaling AL, Prossnitz ER, Hathaway HJ. GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Horm Cancer. 2014; 5: 146-60.

[86] Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000; 14: 1649-60.

[87] Prossnitz ER, Hathaway HJ. What have we learned about GPER function in physiology and disease from knockout mice? J Steroid Biochem Mol Biol. 2015; 153: 114-26.

[88] Nilsson BO, Olde B, Leeb-Lundberg LM. G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling. Br J Pharmacol. 2011; 163: 1131-9.

[89] Waghulde H, Cheng X, Galla S, Mell B, Cai J, Pruett-Miller SM, et al. Attenuation of Microbiotal Dysbiosis and Hypertension in a CRISPR/Cas9 Gene Ablation Rat Model of GPER1. Hypertension. 2018; 72: 1125-32.

[90] Cirillo F, Talia M, Santolla MF, Pellegrino M, Scordamaglia D, Spinelli A, et al. GPER deletion triggers inhibitory effects in triple negative breast cancer (TNBC) cells through the JNK/c-Jun/p53/Noxa transduction pathway. Cell Death Discov. 2023; 9: 353.

[91] Xu E, Xia X, Jiang C, Li Z, Yang Z, Zheng C, et al. GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT-Mediated EMT. Front Cell Dev Biol. 2020; 8: 591239.

[92] Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat. 2010; 123: 87-96.

[93] Molina L, Bustamante F, Ortloff A, Ramos I, Ehrenfeld P, Figueroa CD. Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation. Front Endocrinol (Lausanne). 2020; 11: 563165.

[94] GPER signaling: A central driver of Endocrine Therapy resistance in Breast cancer. Genes Dis. 2025.

[95] Ignatov T, Treeck O, Kalinski T, Ortmann O, Ignatov A. GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients. Arch Gynecol Obstet. 2020; 301: 565-71.

[96] Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat. 2011; 128: 457-66.

[97] Talia M, De Francesco EM, Rigiracciolo DC, Muoio MG, Muglia L, Belfiore A, et al. The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis. Cells. 2020; 9: 622.

[98] Liu L, Liu S, Luo H, Chen C, Zhang X, He L, et al. GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells. Aging (Albany NY). 2021; 13: 16178-97.

[99] Xu T, Ma D, Chen S, Tang R, Yang J, Meng C, et al. High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes. NPJ Breast Cancer. 2022; 8: 100.

[100] Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, et al. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol. 2011; 127: 358-66.

[101] Li XS, Yan Q, Xu XY, Chen WY, Li P, Xiang QL, et al. GPER1 promotes estrogen receptor negative breast cancer cell migration and invasion via non-genomic activation of c-Src/NF-κB/focal adhesion kinase cascade. J Bio-X Res. 2018; 1: 45-55.

[102] Tirado-Garibay AC, Falcón-Ruiz EA, Ochoa-Zarzosa A, López-Meza JE. GPER: An Estrogen Receptor Key in Metastasis and Tumoral Microenvironments. Int J Mol Sci. 2023; 24: 14993.

[103] De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A, Maggiolini M. HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res. 2013; 15: R64.

[104] Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A. 2006; 103: 9063-8.

[105] Su X, Xu X, Li G, Lin B, Cao J, Teng L. ER-α36: a novel biomarker and potential therapeutic target in breast cancer. Onco Targets Ther. 2014; 7: 1525-33.

[106] Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene. 2011; 30: 770-80.

[107] Gu Y, Chen T, López E, Wu W, Wang X, Cao J, et al. The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors. J Transl Med. 2014; 12: 16.

[108] Teymourzadeh A, Mansouri S, Farahmand L, Hosseinzade A, Majidzadeh-A K. ER-α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance. Clin Breast Cancer. 2017; 17: 403-7.

[109] Lin SL, Yan LY, Zhang XT, Yuan J, Li M, Qiao J, et al. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One. 2010; 5: e9013.

[110] Deng H, Zhang XT, Wang ML, Zheng HY, Liu LJ, Wang ZY. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells. PLoS One. 2014; 9: e88034.

[111] Li G, Zhang J, Xu Z, Li Z. ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway. Cancer Manag Res. 2020; 12: 265-75.

[112] Yin L, Zhang XT, Bian XW, Guo YM, Wang ZY. Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells. PLoS One. 2014; 9: e107369.

[113] Sagredo EA, Blanco A, Sagredo AI, Pérez P, Sepúlveda-Hermosilla G, Morales F, et al. ADAR1-mediated RNA-editing of 3’UTRs in breast cancer. Biol Res. 2018; 51: 36.

[114] Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, et al. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol. 2009; 27: 3423-9.

[115] Juliansyah A, Rahman S, Indra I, Nelwan B, Prihantono P. Association of ERα-36 expression with the de novo resistance of tamoxifen in ER-positive breast cancer. Breast Dis. 2021; 40: S123-7.

[116] Wang Q, Jiang J, Ying G, Xie XQ, Zhang X, Xu W, et al. Tamoxifen enhances stemness and promotes metastasis of ERα36⁺ breast cancer by upregulating ALDH1A1 in cancer cells. Cell Res. 2018; 28: 336-58.

[117] Chamard-Jovenin C, Jung AC, Chesnel A, Abecassis J, Flament S, Ledrappier S, et al. From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression. BMC Syst Biol. 2015; 9: 28.

[118] Croci O, De Fazio S, Biagioni F, Donato E, Caganova M, Curti L, et al. Transcriptional integration of mitogenic and mechanical signals by Myc and YAP. Genes Dev. 2017; 31: 2017-22.

[119] Huang X, Zhang M, Pearce AD, Gibbons MD, Jin D, Li L, et al. Epithelial-Mesenchymal Transition Activates YAP to Drive Malignant Progression and Immune Evasion. Cancers (Basel). 2025; 17: 2767.

[120] Park M, Lee SH, Bui QT, Kim YM, Kang KW. The essential role of YAP in ERα36-mediated proliferation and the epithelial-mesenchymal transition in MCF-7 breast cancer cells. Front Pharmacol. 2022; 13: 1057276.

[121] Notas G, Panagiotopoulos A, Vamvoukaki R, Kalyvianaki K, Kiagiadaki F, Deli A, et al. ERα36-GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells. Int J Mol Sci. 2021; 22: 7603.

[122] Saha T, Lukong KE. Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα-positive breast cancer. Front Oncol. 2025; 15: 1513225.

[123] Torres-López L, Olivas-Aguirre M, Dobrovinskaya O. The G Protein-Coupled Estrogen Receptor GPER in the Development and Progression of Cancer. Receptors. 2024; 3: 220-54.

[124] Zhu P, Liao LY, Zhao TT, Mo XM, Chen GG, Liu ZM. GPER/ERK&AKT/NF-κB pathway is involved in cadmium-induced proliferation, invasion and migration of GPER-positive thyroid cancer cells. Mol Cell Endocrinol. 2017; 442: 68-80.

[125] Wang S, Liu F, Han F. MAPK signaling reprogramming via integrative TCM-Western medicine strategy: mechanistic interactions between bioactive herbal components and chemotherapy in ovarian cancer therapy - a comprehensive review. J Ovarian Res. 2025; 19: 82.

[126] Kong D, Hughes CJ, Ford HL. Cellular Plasticity in Breast Cancer Progression and Therapy. Front Mol Biosci. 2020; 7: 72.

[127] Abbas MA, Al-Kabariti AY, Sutton C. Comprehensive understanding of the role of GPER in estrogen receptor-alpha negative breast cancer. J Steroid Biochem Mol Biol. 2024; 241: 106523.

[128] Dama A, Baggio C, Boscaro C, Albiero M, Cignarella A. Estrogen Receptor Functions and Pathways at the Vascular Immune Interface. Int J Mol Sci. 2021; 22: 4254.

[129] Kim KH, Bender JR. Membrane-initiated actions of estrogen on the endothelium. Mol Cell Endocrinol. 2009; 308: 3-8.

[130] Costa TJ, Jiménez-Altayó F, Echem C, Akamine EH, Tostes R, Vila E, et al. Late Onset of Estrogen Therapy Impairs Carotid Function of Senescent Females in Association with Altered Prostanoid Balance and Upregulation of the Variant ERα36. Cells. 2019; 8: 1217.

[131] Clements L, Alexander A, Hamilton K, Irving A, Harvey J. G-protein coupled estrogen receptor (GPER1) activation promotes synaptic insertion of AMPA receptors and induction of chemical LTP at hippocampal temporoammonic-CA1 synapses. Mol Brain. 2023; 16: 16.

[132] Zhang X, Wang ZY. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity. Endocrinology. 2013; 154: 1990-8.

[133] Liu L, Zhou Y, Liu J, Zhang X, He C, Zeng X, et al. GPER in metabolic homeostasis and disease: molecular mechanisms, nutritional regulation, and therapeutic potential. J Transl Med. 2025; 23: 960.

[134] Thomas P, Alyea R, Pang Y, Peyton C, Dong J, Berg AH. Conserved estrogen binding and signaling functions of the G protein-coupled estrogen receptor 1 (GPER) in mammals and fish. Steroids. 2010; 75: 595-602.

[135] Wang H, Ben Menachem-Zidon O, Pandey A, Xiao Y, Deng N, Shi X, et al. G Protein-Coupled Estrogen Receptor Regulates Mesenchymal Stem Cell Mechanotransduction and Differentiation. Cell Mol Bioeng. 2025;[Epub ahead of print].

[136] Plante BJ, Lessey BA, Taylor RN, Wang W, Bagchi MK, Yuan L, et al. G protein-coupled estrogen receptor (GPER) expression in normal and abnormal endometrium. Reprod Sci. 2012; 19: 684-93.

[137] Luo HJ, Luo P, Yang GL, Peng QL, Liu MR, Tu G. G-protein Coupled Estrogen Receptor 1 Expression in Primary Breast Cancers and Its Correlation with Clinicopathological Variables. J Breast Cancer. 2011; 14: 185-90.

[138] Omarjee S, Jacquemetton J, Poulard C, Rochel N, Dejaegere A, Chebaro Y, et al. The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancer. Oncogene. 2017; 36: 2503-14.

[139] Garan LAW, Xiao Y, Lin WC. 14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer. Proc Natl Acad Sci U S A. 2022; 119: e2209211119.

[140] Molina L, Bustamante FA, Bhoola KD, Figueroa CD, Ehrenfeld P. Possible role of phytoestrogens in breast cancer via GPER-1/GPR30 signaling. Clin Sci (Lond). 2018; 132: 2583-98.

[141] Callard GV, Tarrant AM, Novillo A, Yacci P, Ciaccia L, Vajda S, et al. Evolutionary origins of the estrogen signaling system: insights from amphioxus. J Steroid Biochem Mol Biol. 2011; 127: 176-88.

[142] Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, et al. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol. 2010; 24: 709-21.

[143] Gonzalez de Valdivia E, Broselid S, Kahn R, Olde B, Leeb-Lundberg LMF. G protein-coupled estrogen receptor 1 (GPER1)/GPR30 increases ERK1/2 activity through PDZ motif-dependent and -independent mechanisms. J Biol Chem. 2017; 292: 9932-43.

[144] Rodenas MC, Tamassia N, Cabas I, Calzetti F, Meseguer J, Cassatella MA, et al. G Protein-Coupled Estrogen Receptor 1 Regulates Human Neutrophil Functions. Biomed Hub. 2017; 2: 1-13.

[145] Li Z, Pan Y, Liu Q, Wang J, Liu C, Qu L, et al. Role of GPER1 in the Mechanism of EGFR-TKIs Resistance in Lung Adenocarcinoma. Front Oncol. 2022; 12: 869113.

[146] Périan S, Vanacker JM. GPER as a Receptor for Endocrine-Disrupting Chemicals (EDCs). Front Endocrinol. 2020; 11: 545.

[147] Xiao T, Li W, Wang X, Xu H, Yang J, Wu Q, et al. Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. Proc Natl Acad Sci U S A. 2018; 115: 7869-78.

[148] Drula R, Pardini B, Fu X, De Los Santos MC, Jurj A, Pang L, et al. 17β-estradiol promotes extracellular vesicle release and selective miRNA loading in ERα-positive breast cancer. Proc Natl Acad Sci U S A. 2023; 120: e2122053120.

[149] Gui Y, Peng M, Huang Y, Chen Z, Chen J, Xiao J, et al. New insights into extracellular vesicles in metastatic cancer: From mechanisms to diagnostics and targeted therapies. Mol Ther. 2025; 33: 4731-47.

[150] Wnuk A, Przepiórska K, Pietrzak BA, Kajta M. Emerging Evidence on Membrane Estrogen Receptors as Novel Therapeutic Targets for Central Nervous System Pathologies. Int J Mol Sci. 2023; 24: 4043.

[151] Abels ER, Breakefield XO. Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake. Cell Mol Neurobiol. 2016; 36: 301-12.

[152] Cheng SB, Quinn JA, Graeber CT, Filardo EJ. Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a trans-Golgi-proteasome pathway. J Biol Chem. 2011; 286: 22441-55.

[153] Ahmadian Elmi M, Motamed N, Picard D. Proteomic Analyses of the G Protein-Coupled Estrogen Receptor GPER1 Reveal Constitutive Links to Endoplasmic Reticulum, Glycosylation, Trafficking, and Calcium Signaling. Cells. 2023; 12: 2571.

[154] Jin Y, Ma L, Zhang W, Yang W, Feng Q, Wang H. Extracellular signals regulate the biogenesis of extracellular vesicles. Biol Res. 2022; 55: 35.

[155] Di Niro L, Linders AC, Glynn T, Pegtel DM, Siderius M, Crudden C, et al. G protein-coupled receptors: a gateway to targeting oncogenic EVs? Extracell Vesicles Circ Nucl Acids. 2024; 5: 233-48.

[156] Dong H, Zeng X, Xu J, He C, Sun Z, Liu L, et al. Advances in immune regulation of the G protein-coupled estrogen receptor. Int Immunopharmacol. 2024; 136: 112369.

[157] Schreier B, Dubourg V, Hübschmann S, Rabe S, Mildenberger S, Gekle M. Synergy of epidermal growth factor (EGFR) and angiotensin II (AT1R) receptor determines composition and temporal pattern of transcriptome variation. Cell Mol Life Sci. 2021; 79: 57.

[158] Bebelman MP, Crudden C, Pegtel DM, Smit MJ. The Convergence of Extracellular Vesicle and GPCR Biology. Trends Pharmacol Sci. 2020; 41: 627-40.

[159] Romano SN, Gorelick DA. Crosstalk between nuclear and G protein-coupled estrogen receptors. Gen Comp Endocrinol. 2018; 261: 190-7.

[160] Sauer SJ, Tarpley M, Shah I, Save AV, Lyerly HK, Patierno SR, et al. Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis. 2017; 38: 252-60.

[161] Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol. 2009; 308: 32-8.

[162] Saatci O, Huynh-Dam KT, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med (Berl). 2021; 99: 1691-710.

[163] Rusciano D. Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy Response. J Pers Med. 2026; 16: 176.

[164] Czaczkowska L, Jabłońska E, Ratajczak-Wrona W. Endocrine Disruptors and Breast Cancer: A Comprehensive Review. Biomedicines. 2025; 13: 2774.

[165] Stillwater BJ, Bull AC, Romagnolo DF, Neumayer LA, Donovan MG, Selmin OI. Bisphenols and Risk of Breast Cancer: A Narrative Review of the Impact of Diet and Bioactive Food Components. Front Nutr. 2020; 7: 581388.

[166] Calaf GM, Ponce-Cusi R, Aguayo F, Muñoz JP, Bleak TC. Endocrine disruptors from the environment affecting breast cancer. Oncol Lett. 2020; 20: 19-32.

[167] Gonzalez TL, Rae JM, Colacino JA. Implication of environmental estrogens on breast cancer treatment and progression. Toxicology. 2019; 421: 41-8.

[168] Williams GP, Darbre PD. Low-dose environmental endocrine disruptors, increase aromatase activity, estradiol biosynthesis and cell proliferation in human breast cells. Mol Cell Endocrinol. 2019; 486: 55-64.

[169] Parrish M, Kuperwasser C. Environmental endocrine disruptors: rethinking the origins of early-onset ER⁺ breast cancer. Nat Rev Cancer. 2025; 25: 819-20.

[170] Al-Ani M, Al-Ani Y, Ibrahim SS, Ibrahim RS, Kubatka P, Büsselberg D. Bisphenol A (BPA) Modifies Cancer Signaling Pathways: A Neglected Global Health Threat. J Xenobiot. 2025; 15: 207.

[171] Qu C, Wang C, Li H, Li Y, Han C, Tao X, et al. Estrogen receptor variant ER-α36 facilitates estrogen signaling via EGFR in glioblastoma. Cell Biol Int. 2022; 46: 1759-74.

[172] Patterson AR, Mo X, Shapiro A, Wernke KE, Archer TK, Burd CJ. Sustained reprogramming of the estrogen response after chronic exposure to endocrine disruptors. Mol Endocrinol. 2015; 29: 384-95.

[173] Thiebaut C, Chesnel A, Merlin JL, Chesnel M, Leroux A, Harlé A, et al. Dual Epigenetic Regulation of ERα36 Expression in Breast Cancer Cells. Int J Mol Sci. 2019; 20: 2637.

[174] Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol. 2002; 80: 231-8.

[175] Konan HP, Kassem L, Omarjee S, Surmieliova-Garnès A, Jacquemetton J, Cascales E, et al. ERα-36 regulates progesterone receptor activity in breast cancer. Breast Cancer Res. 2020; 22: 50.

[176] Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al.; METABRIC Group; Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486: 346-52.

[177] Neubauer H, Clare SE, Wozny W, Schwall GP, Poznanovic S, Stegmann W, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res. 2008; 10: R85.

[178] Martin SG, Lebot MN, Sukkarn B, Ball G, Green AR, Rakha EA, et al. Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients. Oncotarget. 2018; 9: 25946-56.

[179] Meng R, Qin Q, Xiong Y, Wang Y, Zheng J, Zhao Y, et al. NHERF1, a novel GPER associated protein, increases stability and activation of GPER in ER-positive breast cancer. Oncotarget. 2016; 7: 54983-97.

[180] Zhou X, Wang S, Wang Z, Feng X, Liu P, Lv XB, et al. Estrogen regulates Hippo signaling via GPER in breast cancer. J Clin Invest. 2015; 125: 2123-35.

[181] Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015; 24 Suppl 2: S26-35.

[182] Lombardi V, Di Rocco L, Meo E, Venafra V, Di Nisio E, Perticaroli V, et al. PatientProfiler: building patient-specific signaling models from proteogenomic data. Mol Syst Biol. 2025; 21: 1845-65.